A Multicenter, Randomized, Double-Blind Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets in Patients With Mild to Moderate Essential Hypertension Not Controlled After 4 Weeks of Monotherapy With Amlodipine Or Levamlodipine Alone
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs Levamlodipine (Primary) ; Levamlodipine/valsartan (Primary) ; Valsartan
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors CSPC ZhongQi Pharmaceutical Technology
- 21 Jan 2025 New trial record